In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections

Rinzo Soejima; Masaru Sumi; Niro Okimoto; Chikara Nakahama; Masakichi Motomiya; Akira Watanabe; Tsukasa Yoshida; Kenichi Takeuchi; Toshiharu Ito; Kosaku Nagai; Hiroyuki Kobayashi; Hiroshi Oshitani; Shigeki Odagiri; Kaneo Suzuki; Yasutsugu Amano; Toshiharu Matsushima; Makoto Kimura; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Hidemi Teramoto; Tatsuya Konishi; Toru Hikita; Michio Yamakido; Kenji Hasegawa; Naoki Yamaoka; Naomi Kodomari; Naoshi Saeki; Kazuaki Goriki; Kenichiro Sadamoto; Toyofumi Mitsuyama; Kohei Hara; Shigeru Kouno; Hironobu Koga; Mitsuo Kaku; Kazuhiro Okuno; Kenji Kawano; Masao Nakatomi; Noriyo Fujita; Akira Yasuoka; Masaru Nasu; Hideaki Shigeno; Yoichiro Goto; Tohru Yamasaki; Hiroyuki Nagai; Kenshi Sato; Jun Goto; Mitsunobu Akashi; Yoritsugu Harada; Saburo Uragami; Hiroshi Nagaoka; Kaoru Nakama; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Hiroshi Fukuhara; Masaru Morine; Masanori Uezu

doi:10.11250/chemotherapy1953.40.60

In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections

Rinzo Soejima, Masaru Sumi, Niro Okimoto, Chikara Nakahama, Masakichi Motomiya, Akira Watanabe, Tsukasa Yoshida, Kenichi Takeuchi, Toshiharu Ito, Kosaku Nagai, Hiroyuki Kobayashi, Hiroshi Oshitani, Shigeki Odagiri, Kaneo Suzuki, Yasutsugu Amano, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji SugimotoHidemi Teramoto, Tatsuya Konishi, Toru Hikita, Michio Yamakido, Kenji Hasegawa, Naoki Yamaoka, Naomi Kodomari, Naoshi Saeki, Kazuaki Goriki, Kenichiro Sadamoto, Toyofumi Mitsuyama, Kohei Hara, Shigeru Kouno, Hironobu Koga, Mitsuo Kaku, Kazuhiro Okuno, Kenji Kawano, Masao Nakatomi, Noriyo Fujita, Akira Yasuoka, Masaru Nasu, Hideaki Shigeno, Yoichiro Goto, Tohru Yamasaki, Hiroyuki Nagai, Kenshi Sato, Jun Goto, Mitsunobu Akashi, Yoritsugu Harada, Saburo Uragami, Hiroshi Nagaoka, Kaoru Nakama, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Masaru Morine, Masanori Uezu

Research output: Contribution to journal › Article › peer-review

Abstract

We carried out bacteriological and clinical studies on intramuscular imipenem/cilastatin sodium (IPM/CS) developed as a new route of administration and obtained the following results. 1. Antimicrobial activity The In vitro antimicrobial activity of imipenem (IPM) against 330 clinical isolates of 11 species was determined and compared with that of piperacillin (PIPC), cefazolin (CEZ), cefotiam (CTM), aztreonam (AZT), sulbactam/cefoperazone (SBT/CPZ), ceftazidime (CAZ), minocycline (MING) and amikacin (AMK). The M IC₉₀ of IPM was 8 µg/ml against Pseudomonas aeruginosa and 1 µg/ml or less against the other organisms, except for methicillin-resistant Staphylococcus aureus (MRSA), whose MIC₉₀ was 128 µg/ml. 2. Clinical efficacy and safety 0.25 g/0.25 g or 0.5 g/0.5 g of intramuscular IPM/CS was administered twice a day for 2–16 days to 62 patients with respiratory tract infections, and clinical efficacy and safety were evaluated. Clinical efficacy in 60 evaluable patients was excellent in 12 patients, good in 33, fair in 10 and poor in 5, with an efficacy rating of 75.0%. The bacteriological eradication rate was 79.3%. Of the 61 patients evaluable for safety, gastrointestinal symptoms such as diarrhea were observed in 3 patients, and inflammation at the injection site and aggravation of pain/numbness in the lower extremities each occurred in one patient, resulting in a total of 5'patients with adverse experiences (8.2%). These improved after discontinuation or completion of the treatment. Abnormal laboratory findings such as abnormalities in liver function tests were observed in 13 patients; however, these findings were mild and transient.

Original language	English
Pages (from-to)	60-74
Number of pages	15
Journal	Chemotherapy
Volume	40
Issue number	1
DOIs	https://doi.org/10.11250/chemotherapy1953.40.60
Publication status	Published - 1992 Jan
Externally published	Yes

Keywords

IPM/CS
MIC
imipenem/cilastatin sodium

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.60

Cite this

Soejima, R., Sumi, M., Okimoto, N., Nakahama, C., Motomiya, M., Watanabe, A., Yoshida, T., Takeuchi, K., Ito, T., Nagai, K., Kobayashi, H., Oshitani, H., Odagiri, S., Suzuki, K., Amano, Y., Matsushima, T., Kimura, M., Sasaki, T., Matsumoto, Y., ... Uezu, M. (1992). In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections. Chemotherapy, 40(1), 60-74. https://doi.org/10.11250/chemotherapy1953.40.60

Soejima, R, Sumi, M, Okimoto, N, Nakahama, C, Motomiya, M, Watanabe, A, Yoshida, T, Takeuchi, K, Ito, T, Nagai, K, Kobayashi, H, Oshitani, H, Odagiri, S, Suzuki, K, Amano, Y, Matsushima, T, Kimura, M, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Teramoto, H, Konishi, T, Hikita, T, Yamakido, M, Hasegawa, K, Yamaoka, N, Kodomari, N, Saeki, N, Goriki, K, Sadamoto, K, Mitsuyama, T, Hara, K, Kouno, S, Koga, H, Kaku, M, Okuno, K, Kawano, K, Nakatomi, M, Fujita, N, Yasuoka, A, Nasu, M, Shigeno, H, Goto, Y, Yamasaki, T, Nagai, H, Sato, K, Goto, J, Akashi, M, Harada, Y, Uragami, S, Nagaoka, H, Nakama, K, Saito, A, Shigeno, Y, Irabu, Y, Fukuhara, H, Morine, M & Uezu, M 1992, 'In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections', Chemotherapy, vol. 40, no. 1, pp. 60-74. https://doi.org/10.11250/chemotherapy1953.40.60

@article{48ba6a7513504cbf95a80337a57804ce,

title = "In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections",

abstract = "We carried out bacteriological and clinical studies on intramuscular imipenem/cilastatin sodium (IPM/CS) developed as a new route of administration and obtained the following results. 1. Antimicrobial activity The In vitro antimicrobial activity of imipenem (IPM) against 330 clinical isolates of 11 species was determined and compared with that of piperacillin (PIPC), cefazolin (CEZ), cefotiam (CTM), aztreonam (AZT), sulbactam/cefoperazone (SBT/CPZ), ceftazidime (CAZ), minocycline (MING) and amikacin (AMK). The M IC90 of IPM was 8 µg/ml against Pseudomonas aeruginosa and 1 µg/ml or less against the other organisms, except for methicillin-resistant Staphylococcus aureus (MRSA), whose MIC90 was 128 µg/ml. 2. Clinical efficacy and safety 0.25 g/0.25 g or 0.5 g/0.5 g of intramuscular IPM/CS was administered twice a day for 2–16 days to 62 patients with respiratory tract infections, and clinical efficacy and safety were evaluated. Clinical efficacy in 60 evaluable patients was excellent in 12 patients, good in 33, fair in 10 and poor in 5, with an efficacy rating of 75.0%. The bacteriological eradication rate was 79.3%. Of the 61 patients evaluable for safety, gastrointestinal symptoms such as diarrhea were observed in 3 patients, and inflammation at the injection site and aggravation of pain/numbness in the lower extremities each occurred in one patient, resulting in a total of 5'patients with adverse experiences (8.2%). These improved after discontinuation or completion of the treatment. Abnormal laboratory findings such as abnormalities in liver function tests were observed in 13 patients; however, these findings were mild and transient.",

keywords = "IPM/CS, MIC, imipenem/cilastatin sodium",

author = "Rinzo Soejima and Masaru Sumi and Niro Okimoto and Chikara Nakahama and Masakichi Motomiya and Akira Watanabe and Tsukasa Yoshida and Kenichi Takeuchi and Toshiharu Ito and Kosaku Nagai and Hiroyuki Kobayashi and Hiroshi Oshitani and Shigeki Odagiri and Kaneo Suzuki and Yasutsugu Amano and Toshiharu Matsushima and Makoto Kimura and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Hidemi Teramoto and Tatsuya Konishi and Toru Hikita and Michio Yamakido and Kenji Hasegawa and Naoki Yamaoka and Naomi Kodomari and Naoshi Saeki and Kazuaki Goriki and Kenichiro Sadamoto and Toyofumi Mitsuyama and Kohei Hara and Shigeru Kouno and Hironobu Koga and Mitsuo Kaku and Kazuhiro Okuno and Kenji Kawano and Masao Nakatomi and Noriyo Fujita and Akira Yasuoka and Masaru Nasu and Hideaki Shigeno and Yoichiro Goto and Tohru Yamasaki and Hiroyuki Nagai and Kenshi Sato and Jun Goto and Mitsunobu Akashi and Yoritsugu Harada and Saburo Uragami and Hiroshi Nagaoka and Kaoru Nakama and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Hiroshi Fukuhara and Masaru Morine and Masanori Uezu",

year = "1992",

month = jan,

doi = "10.11250/chemotherapy1953.40.60",

language = "English",

volume = "40",

pages = "60--74",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "1",

}

TY - JOUR

T1 - In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections

AU - Soejima, Rinzo

AU - Sumi, Masaru

AU - Okimoto, Niro

AU - Nakahama, Chikara

AU - Motomiya, Masakichi

AU - Watanabe, Akira

AU - Yoshida, Tsukasa

AU - Takeuchi, Kenichi

AU - Ito, Toshiharu

AU - Nagai, Kosaku

AU - Kobayashi, Hiroyuki

AU - Oshitani, Hiroshi

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Amano, Yasutsugu

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Teramoto, Hidemi

AU - Konishi, Tatsuya

AU - Hikita, Toru

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Yamaoka, Naoki

AU - Kodomari, Naomi

AU - Saeki, Naoshi

AU - Goriki, Kazuaki

AU - Sadamoto, Kenichiro

AU - Mitsuyama, Toyofumi

AU - Hara, Kohei

AU - Kouno, Shigeru

AU - Koga, Hironobu

AU - Kaku, Mitsuo

AU - Okuno, Kazuhiro

AU - Kawano, Kenji

AU - Nakatomi, Masao

AU - Fujita, Noriyo

AU - Yasuoka, Akira

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Goto, Yoichiro

AU - Yamasaki, Tohru

AU - Nagai, Hiroyuki

AU - Sato, Kenshi

AU - Goto, Jun

AU - Akashi, Mitsunobu

AU - Harada, Yoritsugu

AU - Uragami, Saburo

AU - Nagaoka, Hiroshi

AU - Nakama, Kaoru

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Morine, Masaru

AU - Uezu, Masanori

PY - 1992/1

Y1 - 1992/1

N2 - We carried out bacteriological and clinical studies on intramuscular imipenem/cilastatin sodium (IPM/CS) developed as a new route of administration and obtained the following results. 1. Antimicrobial activity The In vitro antimicrobial activity of imipenem (IPM) against 330 clinical isolates of 11 species was determined and compared with that of piperacillin (PIPC), cefazolin (CEZ), cefotiam (CTM), aztreonam (AZT), sulbactam/cefoperazone (SBT/CPZ), ceftazidime (CAZ), minocycline (MING) and amikacin (AMK). The M IC90 of IPM was 8 µg/ml against Pseudomonas aeruginosa and 1 µg/ml or less against the other organisms, except for methicillin-resistant Staphylococcus aureus (MRSA), whose MIC90 was 128 µg/ml. 2. Clinical efficacy and safety 0.25 g/0.25 g or 0.5 g/0.5 g of intramuscular IPM/CS was administered twice a day for 2–16 days to 62 patients with respiratory tract infections, and clinical efficacy and safety were evaluated. Clinical efficacy in 60 evaluable patients was excellent in 12 patients, good in 33, fair in 10 and poor in 5, with an efficacy rating of 75.0%. The bacteriological eradication rate was 79.3%. Of the 61 patients evaluable for safety, gastrointestinal symptoms such as diarrhea were observed in 3 patients, and inflammation at the injection site and aggravation of pain/numbness in the lower extremities each occurred in one patient, resulting in a total of 5'patients with adverse experiences (8.2%). These improved after discontinuation or completion of the treatment. Abnormal laboratory findings such as abnormalities in liver function tests were observed in 13 patients; however, these findings were mild and transient.

AB - We carried out bacteriological and clinical studies on intramuscular imipenem/cilastatin sodium (IPM/CS) developed as a new route of administration and obtained the following results. 1. Antimicrobial activity The In vitro antimicrobial activity of imipenem (IPM) against 330 clinical isolates of 11 species was determined and compared with that of piperacillin (PIPC), cefazolin (CEZ), cefotiam (CTM), aztreonam (AZT), sulbactam/cefoperazone (SBT/CPZ), ceftazidime (CAZ), minocycline (MING) and amikacin (AMK). The M IC90 of IPM was 8 µg/ml against Pseudomonas aeruginosa and 1 µg/ml or less against the other organisms, except for methicillin-resistant Staphylococcus aureus (MRSA), whose MIC90 was 128 µg/ml. 2. Clinical efficacy and safety 0.25 g/0.25 g or 0.5 g/0.5 g of intramuscular IPM/CS was administered twice a day for 2–16 days to 62 patients with respiratory tract infections, and clinical efficacy and safety were evaluated. Clinical efficacy in 60 evaluable patients was excellent in 12 patients, good in 33, fair in 10 and poor in 5, with an efficacy rating of 75.0%. The bacteriological eradication rate was 79.3%. Of the 61 patients evaluable for safety, gastrointestinal symptoms such as diarrhea were observed in 3 patients, and inflammation at the injection site and aggravation of pain/numbness in the lower extremities each occurred in one patient, resulting in a total of 5'patients with adverse experiences (8.2%). These improved after discontinuation or completion of the treatment. Abnormal laboratory findings such as abnormalities in liver function tests were observed in 13 patients; however, these findings were mild and transient.

KW - IPM/CS

KW - MIC

KW - imipenem/cilastatin sodium

UR - http://www.scopus.com/inward/record.url?scp=0026513047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026513047&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.60

DO - 10.11250/chemotherapy1953.40.60

M3 - Article

AN - SCOPUS:0026513047

VL - 40

SP - 60

EP - 74

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 1

ER -

In vitro antimicrobial activity of imipenem and clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in respiratory tract infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this